Sponsor classes split the disclosure problem in different ways

OTHER_GOV is worst on rate, OTHER is worst on stock, and industry remains too large to dismiss.

Rate vs stock

OTHER_GOV

OTHER

Industry still large

Dashboard

The sponsor-class story only becomes legible when rate and stock are plotted separately.

How to read the dashboard

Closed interventional

290,524

All sponsor classes

Eligible older

249,507

2-year denominator

Worst rate

95.7%

OTHER_GOV

Largest stock

127,704

OTHER

Rates

Rate identifies systematic opacity. OTHER_GOV is the standout class on this axis.

High rate signals a class where non-reporting looks systematic rather than merely a consequence of very large scale.

Stock

Absolute stock identifies where the largest unseen block sits, and that block belongs to OTHER.

Volume matters because unresolved stock determines how much public evidence is still effectively missing from the registry surface.

Read Across Projects

Each project isolates a different dimension of registry opacity, but the point is the contrast between them, not a single leaderboard.

A standalone E156 project on how much long-past non-disclosure and structural sparsity remain inside industry-linked ClinicalTrials.gov records.

A standalone E156 project on how reporting gaps change by trial phase, showing that phase structure matters alongside sponsor class.

A standalone E156 project on the descriptive fields that disappear from ClinicalTrials.gov even before results reporting is considered.